...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Re: Resverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalone's Potential Therapeutic Benefits

There are 11 Trials underway with ZENE and its Partners. All are to finish by year end hereĀ 

in 2024.

7 are supposedly competed by June of this year. What data will be released and when,,who knows,,,all will be a big secret no doubt.

One could surmise that good results would give a Partner the initiative to make an offer of some sort. We still have no clear vision as to the business model in either company,,,RVX was to be a medium size Pharma based on pinocchios drivel...ZENE, the satellite nursery, was to be birthing new molecules at a blinding rate, and thatĀ  as we know hasnt quite developed after 11 years,,so what is a holder to make of it all?...No outside investment interest has been seen for years. Possibly the debt and the IP collateral has all scared off,,and rightly so!

Share
New Message
Please login to post a reply